Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19

Letter Immunology

IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2

Romain Levy et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Article Medicine, Research & Experimental

An immune-based biomarker signature is associated with mortality in COVID-19 patients

Michael S. Abers et al.

Summary: Immune and inflammatory responses are important factors contributing to disease severity in COVID-19. This study identified specific immune-based biomarkers associated with mortality in COVID-19 patients, with some biomarkers consistently higher in those who died compared to those who recovered, suggesting their potential for early prediction of disease outcome.

JCI INSIGHT (2021)

Add to Collection

Article Immunology

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia

Nicolas de Prost et al.

Summary: This study reported four cases of life-threatening COVID-19 pneumonia in patients with high blood concentrations of neutralizing autoantibodies against type I interferons, who were treated with plasma exchange. The results showed that plasma exchange efficiently removes autoantibodies against type I interferons in these patients without affecting anti-SARS-CoV-2 antibody levels.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Critical Care Medicine

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients

Rutger Koning et al.

INTENSIVE CARE MEDICINE (2021)

Add to Collection

Article Immunology

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Jesus Troya et al.

Summary: In severe cases of COVID-19 pneumonia, approximately 10.6% of patients were found to have autoantibodies neutralizing type I IFN, which correlated with increased C-reactive protein levels and decreased lymphocyte counts, possibly increasing the risk of death. Subcutaneous IFN-beta treatment did not seem to improve clinical outcomes.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Immunology

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2

Paul Bastard et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Paul Bastard et al.

Summary: Patients with biallelic loss-of-function variants of AIRE, suffering from APS-1, produce autoantibodies that neutralize most type I interferons, leading to a significantly increased risk of life-threatening COVID-19 pneumonia. Research has shown that in APS-1 patients with these neutralizing autoantibodies, 86% developed COVID-19 pneumonia.

JOURNAL OF EXPERIMENTAL MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1

Christian Meisel et al.

Summary: This study found that patients with APS-1 and preexisting neutralizing autoantibodies against IFN-alpha and IFN-omega developed only mild symptoms of COVID-19 after contracting SARS-CoV-2, without progressing to severe cases. These patients were mostly female and under the age of 26.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology